Director Koppel Adam buys 1,562,500 shares of KLRA at $16.00 for $25,000,000; 4 other insiders also bought within 14 days
Koppel Adam, a director at Kailera Therapeutics, acquired 1,562,500 shares at $16.00 on 2026-04-20, just 2 trading days after the company's IPO listing. His post-transaction holdings of 22,583,268 shares represent a 7.4% increase from his pre-transaction position of 21,020,768 shares. The filing note indicates this transaction involves a derivative conversion rather than a straightforward open-market purchase, so the reported Table I position does not represent his complete stake. Most significantly, a cluster pattern emerges: 4 other insiders also purchased shares within the past 14 days, suggesting coordinated insider accumulation during the critical early trading window post-IPO. Given the company's 2-trading-day age and the absence of meaningful 52-week reference data, this near-simultaneous multi-insider buying activity warrants close monitoring of the underlying investment thesis and any material developments disclosed at or near the IPO.